nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PTGS1—kidney cancer	0.163	0.522	CbGaD
Bortezomib—CYP1A1—kidney cancer	0.149	0.478	CbGaD
Bortezomib—CYP1A1—Erlotinib—kidney cancer	0.0214	0.0813	CbGbCtD
Bortezomib—CYP2D6—Temsirolimus—kidney cancer	0.021	0.0799	CbGbCtD
Bortezomib—CYP3A4—Everolimus—kidney cancer	0.0197	0.0752	CbGbCtD
Bortezomib—CYP2C8—Pazopanib—kidney cancer	0.0173	0.0658	CbGbCtD
Bortezomib—CYP1A2—Pazopanib—kidney cancer	0.0134	0.0509	CbGbCtD
Bortezomib—CYP3A4—Temsirolimus—kidney cancer	0.0133	0.0508	CbGbCtD
Bortezomib—CYP2C9—Capecitabine—kidney cancer	0.0126	0.0478	CbGbCtD
Bortezomib—CYP2C8—Erlotinib—kidney cancer	0.0123	0.0469	CbGbCtD
Bortezomib—CYP2C8—Paclitaxel—kidney cancer	0.0113	0.043	CbGbCtD
Bortezomib—CYP2D6—Pazopanib—kidney cancer	0.011	0.0419	CbGbCtD
Bortezomib—CYP2C8—Sorafenib—kidney cancer	0.01	0.0382	CbGbCtD
Bortezomib—CYP1A2—Erlotinib—kidney cancer	0.00954	0.0363	CbGbCtD
Bortezomib—CYP2C19—Sorafenib—kidney cancer	0.00841	0.032	CbGbCtD
Bortezomib—CYP2C9—Paclitaxel—kidney cancer	0.00787	0.03	CbGbCtD
Bortezomib—CYP2D6—Erlotinib—kidney cancer	0.00786	0.0299	CbGbCtD
Bortezomib—CYP1A2—Sorafenib—kidney cancer	0.00776	0.0295	CbGbCtD
Bortezomib—CYP3A4—Pazopanib—kidney cancer	0.007	0.0267	CbGbCtD
Bortezomib—CYP2C9—Sorafenib—kidney cancer	0.00699	0.0266	CbGbCtD
Bortezomib—CYP2D6—Sorafenib—kidney cancer	0.00639	0.0243	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—kidney cancer	0.00631	0.024	CbGbCtD
Bortezomib—CYP3A4—Erlotinib—kidney cancer	0.005	0.019	CbGbCtD
Bortezomib—CYP3A4—Paclitaxel—kidney cancer	0.00457	0.0174	CbGbCtD
Bortezomib—CYP3A4—Sorafenib—kidney cancer	0.00406	0.0155	CbGbCtD
Bortezomib—CYP3A4—Vinblastine—kidney cancer	0.00401	0.0153	CbGbCtD
Bortezomib—CYP3A4—Vincristine—kidney cancer	0.00394	0.015	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—kidney cancer	0.00388	0.0148	CbGbCtD
Bortezomib—CYP3A4—Sunitinib—kidney cancer	0.00329	0.0125	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—kidney cancer	0.00247	0.00939	CbGbCtD
Bortezomib—PSMA1—renal system—kidney cancer	0.00227	0.0377	CbGeAlD
Bortezomib—CTSG—cardiac atrium—kidney cancer	0.00211	0.0351	CbGeAlD
Bortezomib—PSMD1—nephron tubule—kidney cancer	0.00209	0.0348	CbGeAlD
Bortezomib—PSMA1—gonad—kidney cancer	0.00203	0.0338	CbGeAlD
Bortezomib—CYP2C19—urine—kidney cancer	0.00188	0.0313	CbGeAlD
Bortezomib—PSMD2—nephron tubule—kidney cancer	0.00185	0.0308	CbGeAlD
Bortezomib—PSMD1—cortex of kidney—kidney cancer	0.00179	0.0298	CbGeAlD
Bortezomib—PSMD1—cardiac atrium—kidney cancer	0.0017	0.0283	CbGeAlD
Bortezomib—PSMD2—renal system—kidney cancer	0.00168	0.028	CbGeAlD
Bortezomib—PSMD2—kidney—kidney cancer	0.00163	0.0271	CbGeAlD
Bortezomib—PSMB5—nephron tubule—kidney cancer	0.00163	0.027	CbGeAlD
Bortezomib—PSMD2—cortex of kidney—kidney cancer	0.00159	0.0264	CbGeAlD
Bortezomib—PSMB8—cortex of kidney—kidney cancer	0.00158	0.0262	CbGeAlD
Bortezomib—CYP1A2—urine—kidney cancer	0.00154	0.0256	CbGeAlD
Bortezomib—PSMD2—gonad—kidney cancer	0.00151	0.0251	CbGeAlD
Bortezomib—PSMD2—cardiac atrium—kidney cancer	0.00151	0.0251	CbGeAlD
Bortezomib—CYP2C9—urine—kidney cancer	0.00146	0.0243	CbGeAlD
Bortezomib—PSMB1—nephron tubule—kidney cancer	0.00142	0.0236	CbGeAlD
Bortezomib—PSMB5—cortex of kidney—kidney cancer	0.00139	0.0232	CbGeAlD
Bortezomib—PSMB2—nephron tubule—kidney cancer	0.00139	0.0231	CbGeAlD
Bortezomib—PSMB5—cardiac atrium—kidney cancer	0.00132	0.022	CbGeAlD
Bortezomib—PSMB1—renal system—kidney cancer	0.00129	0.0215	CbGeAlD
Bortezomib—PSMB2—renal system—kidney cancer	0.00126	0.021	CbGeAlD
Bortezomib—PSMB1—kidney—kidney cancer	0.00125	0.0208	CbGeAlD
Bortezomib—PSMB2—kidney—kidney cancer	0.00122	0.0203	CbGeAlD
Bortezomib—PSMB1—cortex of kidney—kidney cancer	0.00122	0.0202	CbGeAlD
Bortezomib—SLC31A1—nephron tubule—kidney cancer	0.0012	0.02	CbGeAlD
Bortezomib—PSMB2—cortex of kidney—kidney cancer	0.00119	0.0197	CbGeAlD
Bortezomib—PSMB1—gonad—kidney cancer	0.00116	0.0193	CbGeAlD
Bortezomib—PSMB1—cardiac atrium—kidney cancer	0.00116	0.0192	CbGeAlD
Bortezomib—PSMB2—gonad—kidney cancer	0.00113	0.0188	CbGeAlD
Bortezomib—PSMB2—cardiac atrium—kidney cancer	0.00113	0.0188	CbGeAlD
Bortezomib—CYP3A4—urine—kidney cancer	0.00111	0.0185	CbGeAlD
Bortezomib—CYP2D6—urine—kidney cancer	0.0011	0.0182	CbGeAlD
Bortezomib—SLC31A1—renal system—kidney cancer	0.00109	0.0182	CbGeAlD
Bortezomib—SLC31A1—kidney—kidney cancer	0.00106	0.0176	CbGeAlD
Bortezomib—SLC31A1—cortex of kidney—kidney cancer	0.00103	0.0171	CbGeAlD
Bortezomib—SLC31A1—gonad—kidney cancer	0.00098	0.0163	CbGeAlD
Bortezomib—SLC31A1—cardiac atrium—kidney cancer	0.000978	0.0163	CbGeAlD
Bortezomib—PSMD1—Temsirolimus—Everolimus—kidney cancer	0.00093	0.224	CbGdCrCtD
Bortezomib—PSMB5—Everolimus—Temsirolimus—kidney cancer	0.00093	0.224	CbGdCrCtD
Bortezomib—Lacosamide—CA9—kidney cancer	0.000783	0.432	CrCbGaD
Bortezomib—PSMB8—Tacrolimus—Everolimus—kidney cancer	0.000749	0.181	CbGdCrCtD
Bortezomib—PSMB8—Tacrolimus—Temsirolimus—kidney cancer	0.000749	0.181	CbGdCrCtD
Bortezomib—Lacosamide—CA2—kidney cancer	0.000704	0.388	CrCbGaD
Bortezomib—CYP2C8—renal system—kidney cancer	0.000402	0.00668	CbGeAlD
Bortezomib—CYP2C8—kidney—kidney cancer	0.000389	0.00646	CbGeAlD
Bortezomib—CYP1A2—renal system—kidney cancer	0.000376	0.00625	CbGeAlD
Bortezomib—CYP1A1—renal system—kidney cancer	0.000371	0.00617	CbGeAlD
Bortezomib—CYP1A1—kidney—kidney cancer	0.000359	0.00596	CbGeAlD
Bortezomib—CYP1A1—cardiac atrium—kidney cancer	0.000332	0.00552	CbGeAlD
Bortezomib—PTGS1—renal system—kidney cancer	0.000326	0.00542	CbGeAlD
Bortezomib—Nateglinide—PTGS1—kidney cancer	0.000326	0.18	CrCbGaD
Bortezomib—PTGS1—kidney—kidney cancer	0.000315	0.00524	CbGeAlD
Bortezomib—PTGS1—cardiac atrium—kidney cancer	0.000292	0.00485	CbGeAlD
Bortezomib—CYP3A4—renal system—kidney cancer	0.000272	0.00453	CbGeAlD
Bortezomib—CYP2D6—renal system—kidney cancer	0.000268	0.00445	CbGeAlD
Bortezomib—CYP3A4—kidney—kidney cancer	0.000263	0.00438	CbGeAlD
Bortezomib—CYP2D6—kidney—kidney cancer	0.000259	0.00431	CbGeAlD
Bortezomib—PSMB8—Everolimus—Temsirolimus—kidney cancer	0.000215	0.0518	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Gemcitabine—kidney cancer	0.000161	0.0389	CbGdCrCtD
Bortezomib—PSMB8—Vinorelbine—Vincristine—kidney cancer	0.000143	0.0346	CbGdCrCtD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—kidney cancer	0.000143	0.0346	CbGdCrCtD
Bortezomib—PSMB8—Vincristine—Vinblastine—kidney cancer	0.000123	0.0296	CbGdCrCtD
Bortezomib—Dehydration—Doxorubicin—kidney cancer	2.62e-05	0.000125	CcSEcCtD
Bortezomib—Anaphylactic shock—Paclitaxel—kidney cancer	2.62e-05	0.000125	CcSEcCtD
Bortezomib—Oedema—Paclitaxel—kidney cancer	2.62e-05	0.000125	CcSEcCtD
Bortezomib—Abdominal pain—Vincristine—kidney cancer	2.6e-05	0.000124	CcSEcCtD
Bortezomib—Body temperature increased—Vincristine—kidney cancer	2.6e-05	0.000124	CcSEcCtD
Bortezomib—Infection—Paclitaxel—kidney cancer	2.6e-05	0.000124	CcSEcCtD
Bortezomib—Flatulence—Capecitabine—kidney cancer	2.59e-05	0.000124	CcSEcCtD
Bortezomib—Dry skin—Doxorubicin—kidney cancer	2.58e-05	0.000123	CcSEcCtD
Bortezomib—Dysgeusia—Capecitabine—kidney cancer	2.58e-05	0.000123	CcSEcCtD
Bortezomib—Dizziness—Sunitinib—kidney cancer	2.58e-05	0.000123	CcSEcCtD
Bortezomib—Feeling abnormal—Gemcitabine—kidney cancer	2.58e-05	0.000123	CcSEcCtD
Bortezomib—Shock—Paclitaxel—kidney cancer	2.57e-05	0.000123	CcSEcCtD
Bortezomib—Vomiting—Sorafenib—kidney cancer	2.57e-05	0.000123	CcSEcCtD
Bortezomib—Orthostatic hypotension—Doxorubicin—kidney cancer	2.57e-05	0.000123	CcSEcCtD
Bortezomib—Abdominal pain upper—Doxorubicin—kidney cancer	2.57e-05	0.000123	CcSEcCtD
Bortezomib—Nervous system disorder—Paclitaxel—kidney cancer	2.57e-05	0.000122	CcSEcCtD
Bortezomib—Hypokalaemia—Doxorubicin—kidney cancer	2.56e-05	0.000122	CcSEcCtD
Bortezomib—Thrombocytopenia—Paclitaxel—kidney cancer	2.56e-05	0.000122	CcSEcCtD
Bortezomib—Tachycardia—Paclitaxel—kidney cancer	2.55e-05	0.000122	CcSEcCtD
Bortezomib—Rash—Sorafenib—kidney cancer	2.55e-05	0.000122	CcSEcCtD
Bortezomib—Dermatitis—Sorafenib—kidney cancer	2.55e-05	0.000122	CcSEcCtD
Bortezomib—Back pain—Capecitabine—kidney cancer	2.55e-05	0.000121	CcSEcCtD
Bortezomib—Breast disorder—Doxorubicin—kidney cancer	2.55e-05	0.000121	CcSEcCtD
Bortezomib—Skin disorder—Paclitaxel—kidney cancer	2.54e-05	0.000121	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	2.54e-05	0.000121	CcSEcCtD
Bortezomib—Headache—Sorafenib—kidney cancer	2.54e-05	0.000121	CcSEcCtD
Bortezomib—Muscle spasms—Capecitabine—kidney cancer	2.53e-05	0.000121	CcSEcCtD
Bortezomib—Hyperhidrosis—Paclitaxel—kidney cancer	2.53e-05	0.000121	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—kidney cancer	2.52e-05	0.00012	CcSEcCtD
Bortezomib—Nasopharyngitis—Doxorubicin—kidney cancer	2.52e-05	0.00012	CcSEcCtD
Bortezomib—Anorexia—Paclitaxel—kidney cancer	2.49e-05	0.000119	CcSEcCtD
Bortezomib—Gastritis—Doxorubicin—kidney cancer	2.49e-05	0.000119	CcSEcCtD
Bortezomib—Muscular weakness—Doxorubicin—kidney cancer	2.48e-05	0.000119	CcSEcCtD
Bortezomib—Vision blurred—Capecitabine—kidney cancer	2.48e-05	0.000118	CcSEcCtD
Bortezomib—Vomiting—Sunitinib—kidney cancer	2.48e-05	0.000118	CcSEcCtD
Bortezomib—Body temperature increased—Gemcitabine—kidney cancer	2.47e-05	0.000118	CcSEcCtD
Bortezomib—Tremor—Capecitabine—kidney cancer	2.47e-05	0.000118	CcSEcCtD
Bortezomib—Rash—Sunitinib—kidney cancer	2.46e-05	0.000117	CcSEcCtD
Bortezomib—Dermatitis—Sunitinib—kidney cancer	2.45e-05	0.000117	CcSEcCtD
Bortezomib—Abdominal distension—Doxorubicin—kidney cancer	2.45e-05	0.000117	CcSEcCtD
Bortezomib—Hypotension—Paclitaxel—kidney cancer	2.45e-05	0.000117	CcSEcCtD
Bortezomib—Ill-defined disorder—Capecitabine—kidney cancer	2.44e-05	0.000117	CcSEcCtD
Bortezomib—Headache—Sunitinib—kidney cancer	2.44e-05	0.000116	CcSEcCtD
Bortezomib—Influenza—Doxorubicin—kidney cancer	2.43e-05	0.000116	CcSEcCtD
Bortezomib—Dysphagia—Doxorubicin—kidney cancer	2.43e-05	0.000116	CcSEcCtD
Bortezomib—Anaemia—Capecitabine—kidney cancer	2.43e-05	0.000116	CcSEcCtD
Bortezomib—Hypersensitivity—Vincristine—kidney cancer	2.43e-05	0.000116	CcSEcCtD
Bortezomib—Nausea—Sorafenib—kidney cancer	2.4e-05	0.000115	CcSEcCtD
Bortezomib—Pancreatitis—Doxorubicin—kidney cancer	2.39e-05	0.000114	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	2.38e-05	0.000114	CcSEcCtD
Bortezomib—Malaise—Capecitabine—kidney cancer	2.37e-05	0.000113	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—kidney cancer	2.37e-05	0.000113	CcSEcCtD
Bortezomib—Insomnia—Paclitaxel—kidney cancer	2.37e-05	0.000113	CcSEcCtD
Bortezomib—Vertigo—Capecitabine—kidney cancer	2.36e-05	0.000113	CcSEcCtD
Bortezomib—Asthenia—Vincristine—kidney cancer	2.36e-05	0.000113	CcSEcCtD
Bortezomib—Syncope—Capecitabine—kidney cancer	2.36e-05	0.000113	CcSEcCtD
Bortezomib—Leukopenia—Capecitabine—kidney cancer	2.36e-05	0.000112	CcSEcCtD
Bortezomib—Paraesthesia—Paclitaxel—kidney cancer	2.35e-05	0.000112	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—kidney cancer	2.34e-05	0.000112	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—kidney cancer	2.34e-05	0.000112	CcSEcCtD
Bortezomib—Dyspnoea—Paclitaxel—kidney cancer	2.33e-05	0.000111	CcSEcCtD
Bortezomib—Palpitations—Capecitabine—kidney cancer	2.33e-05	0.000111	CcSEcCtD
Bortezomib—Rash—Dactinomycin—kidney cancer	2.33e-05	0.000111	CcSEcCtD
Bortezomib—Nausea—Sunitinib—kidney cancer	2.31e-05	0.00011	CcSEcCtD
Bortezomib—Loss of consciousness—Capecitabine—kidney cancer	2.31e-05	0.00011	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—kidney cancer	2.31e-05	0.00011	CcSEcCtD
Bortezomib—Dyspepsia—Paclitaxel—kidney cancer	2.3e-05	0.00011	CcSEcCtD
Bortezomib—Cough—Capecitabine—kidney cancer	2.3e-05	0.00011	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—kidney cancer	2.28e-05	0.000109	CcSEcCtD
Bortezomib—Decreased appetite—Paclitaxel—kidney cancer	2.27e-05	0.000109	CcSEcCtD
Bortezomib—Hypertension—Capecitabine—kidney cancer	2.27e-05	0.000108	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—kidney cancer	2.26e-05	0.000108	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Paclitaxel—kidney cancer	2.26e-05	0.000108	CcSEcCtD
Bortezomib—Fatigue—Paclitaxel—kidney cancer	2.26e-05	0.000108	CcSEcCtD
Bortezomib—Diarrhoea—Vincristine—kidney cancer	2.25e-05	0.000108	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—kidney cancer	2.25e-05	0.000107	CcSEcCtD
Bortezomib—Asthenia—Gemcitabine—kidney cancer	2.24e-05	0.000107	CcSEcCtD
Bortezomib—Arthralgia—Capecitabine—kidney cancer	2.24e-05	0.000107	CcSEcCtD
Bortezomib—Chest pain—Capecitabine—kidney cancer	2.24e-05	0.000107	CcSEcCtD
Bortezomib—Myalgia—Capecitabine—kidney cancer	2.24e-05	0.000107	CcSEcCtD
Bortezomib—Constipation—Paclitaxel—kidney cancer	2.24e-05	0.000107	CcSEcCtD
Bortezomib—Pain—Paclitaxel—kidney cancer	2.24e-05	0.000107	CcSEcCtD
Bortezomib—Anxiety—Capecitabine—kidney cancer	2.23e-05	0.000107	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	2.22e-05	0.000106	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—kidney cancer	2.22e-05	0.000106	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—kidney cancer	2.22e-05	0.000106	CcSEcCtD
Bortezomib—Discomfort—Capecitabine—kidney cancer	2.21e-05	0.000106	CcSEcCtD
Bortezomib—Pruritus—Gemcitabine—kidney cancer	2.21e-05	0.000106	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—kidney cancer	2.2e-05	0.000105	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—kidney cancer	2.2e-05	0.000105	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—kidney cancer	2.19e-05	0.000105	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—kidney cancer	2.18e-05	0.000104	CcSEcCtD
Bortezomib—Dizziness—Vincristine—kidney cancer	2.18e-05	0.000104	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—kidney cancer	2.17e-05	0.000104	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—kidney cancer	2.17e-05	0.000104	CcSEcCtD
Bortezomib—Confusional state—Capecitabine—kidney cancer	2.17e-05	0.000103	CcSEcCtD
Bortezomib—Feeling abnormal—Paclitaxel—kidney cancer	2.16e-05	0.000103	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	2.15e-05	0.000103	CcSEcCtD
Bortezomib—Oedema—Capecitabine—kidney cancer	2.15e-05	0.000102	CcSEcCtD
Bortezomib—Gastrointestinal pain—Paclitaxel—kidney cancer	2.14e-05	0.000102	CcSEcCtD
Bortezomib—Diarrhoea—Gemcitabine—kidney cancer	2.14e-05	0.000102	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—kidney cancer	2.13e-05	0.000102	CcSEcCtD
Bortezomib—Infection—Capecitabine—kidney cancer	2.13e-05	0.000102	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—kidney cancer	2.13e-05	0.000102	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—kidney cancer	2.12e-05	0.000101	CcSEcCtD
Bortezomib—Shock—Capecitabine—kidney cancer	2.11e-05	0.000101	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—kidney cancer	2.11e-05	0.000101	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—kidney cancer	2.11e-05	0.000101	CcSEcCtD
Bortezomib—Nervous system disorder—Capecitabine—kidney cancer	2.11e-05	0.000101	CcSEcCtD
Bortezomib—Thrombocytopenia—Capecitabine—kidney cancer	2.1e-05	0.0001	CcSEcCtD
Bortezomib—Tachycardia—Capecitabine—kidney cancer	2.1e-05	0.0001	CcSEcCtD
Bortezomib—Vomiting—Vincristine—kidney cancer	2.09e-05	0.0001	CcSEcCtD
Bortezomib—Skin disorder—Capecitabine—kidney cancer	2.09e-05	9.95e-05	CcSEcCtD
Bortezomib—Urticaria—Paclitaxel—kidney cancer	2.08e-05	9.92e-05	CcSEcCtD
Bortezomib—Rash—Vincristine—kidney cancer	2.08e-05	9.91e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Capecitabine—kidney cancer	2.08e-05	9.91e-05	CcSEcCtD
Bortezomib—Dermatitis—Vincristine—kidney cancer	2.08e-05	9.9e-05	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—kidney cancer	2.07e-05	9.88e-05	CcSEcCtD
Bortezomib—Abdominal pain—Paclitaxel—kidney cancer	2.07e-05	9.87e-05	CcSEcCtD
Bortezomib—Body temperature increased—Paclitaxel—kidney cancer	2.07e-05	9.87e-05	CcSEcCtD
Bortezomib—Headache—Vincristine—kidney cancer	2.06e-05	9.85e-05	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—kidney cancer	2.05e-05	9.8e-05	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—kidney cancer	2.05e-05	9.77e-05	CcSEcCtD
Bortezomib—Anorexia—Capecitabine—kidney cancer	2.05e-05	9.77e-05	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—kidney cancer	2.04e-05	9.72e-05	CcSEcCtD
Bortezomib—Hypotension—Capecitabine—kidney cancer	2.01e-05	9.58e-05	CcSEcCtD
Bortezomib—Vomiting—Gemcitabine—kidney cancer	1.99e-05	9.48e-05	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—kidney cancer	1.98e-05	9.47e-05	CcSEcCtD
Bortezomib—Rash—Gemcitabine—kidney cancer	1.97e-05	9.41e-05	CcSEcCtD
Bortezomib—Dermatitis—Gemcitabine—kidney cancer	1.97e-05	9.4e-05	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—kidney cancer	1.96e-05	9.35e-05	CcSEcCtD
Bortezomib—Headache—Gemcitabine—kidney cancer	1.96e-05	9.34e-05	CcSEcCtD
Bortezomib—Nausea—Vincristine—kidney cancer	1.96e-05	9.34e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.96e-05	9.34e-05	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—kidney cancer	1.95e-05	9.3e-05	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—kidney cancer	1.95e-05	9.3e-05	CcSEcCtD
Bortezomib—Insomnia—Capecitabine—kidney cancer	1.94e-05	9.27e-05	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—kidney cancer	1.94e-05	9.25e-05	CcSEcCtD
Bortezomib—Paraesthesia—Capecitabine—kidney cancer	1.93e-05	9.2e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Paclitaxel—kidney cancer	1.93e-05	9.2e-05	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—kidney cancer	1.92e-05	9.18e-05	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—kidney cancer	1.92e-05	9.16e-05	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—kidney cancer	1.91e-05	9.14e-05	CcSEcCtD
Bortezomib—Dyspnoea—Capecitabine—kidney cancer	1.91e-05	9.14e-05	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—kidney cancer	1.91e-05	9.12e-05	CcSEcCtD
Bortezomib—Dyspepsia—Capecitabine—kidney cancer	1.89e-05	9.02e-05	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—kidney cancer	1.88e-05	8.96e-05	CcSEcCtD
Bortezomib—Asthenia—Paclitaxel—kidney cancer	1.88e-05	8.96e-05	CcSEcCtD
Bortezomib—Decreased appetite—Capecitabine—kidney cancer	1.87e-05	8.91e-05	CcSEcCtD
Bortezomib—Nausea—Gemcitabine—kidney cancer	1.86e-05	8.86e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.85e-05	8.85e-05	CcSEcCtD
Bortezomib—Fatigue—Capecitabine—kidney cancer	1.85e-05	8.84e-05	CcSEcCtD
Bortezomib—Pruritus—Paclitaxel—kidney cancer	1.85e-05	8.84e-05	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—kidney cancer	1.84e-05	8.79e-05	CcSEcCtD
Bortezomib—Constipation—Capecitabine—kidney cancer	1.84e-05	8.76e-05	CcSEcCtD
Bortezomib—Pain—Capecitabine—kidney cancer	1.84e-05	8.76e-05	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—kidney cancer	1.82e-05	8.69e-05	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—kidney cancer	1.82e-05	8.67e-05	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—kidney cancer	1.81e-05	8.63e-05	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—kidney cancer	1.81e-05	8.63e-05	CcSEcCtD
Bortezomib—Diarrhoea—Paclitaxel—kidney cancer	1.79e-05	8.54e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Capecitabine—kidney cancer	1.77e-05	8.45e-05	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—kidney cancer	1.77e-05	8.44e-05	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—kidney cancer	1.76e-05	8.4e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Capecitabine—kidney cancer	1.76e-05	8.38e-05	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—kidney cancer	1.76e-05	8.38e-05	CcSEcCtD
Bortezomib—Chills—Doxorubicin—kidney cancer	1.75e-05	8.34e-05	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—kidney cancer	1.74e-05	8.31e-05	CcSEcCtD
Bortezomib—Dizziness—Paclitaxel—kidney cancer	1.73e-05	8.26e-05	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—kidney cancer	1.71e-05	8.15e-05	CcSEcCtD
Bortezomib—Urticaria—Capecitabine—kidney cancer	1.71e-05	8.14e-05	CcSEcCtD
Bortezomib—Abdominal pain—Capecitabine—kidney cancer	1.7e-05	8.1e-05	CcSEcCtD
Bortezomib—Body temperature increased—Capecitabine—kidney cancer	1.7e-05	8.1e-05	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—kidney cancer	1.7e-05	8.09e-05	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—kidney cancer	1.7e-05	8.09e-05	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—kidney cancer	1.67e-05	7.98e-05	CcSEcCtD
Bortezomib—Vomiting—Paclitaxel—kidney cancer	1.66e-05	7.94e-05	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—kidney cancer	1.66e-05	7.93e-05	CcSEcCtD
Bortezomib—Rash—Paclitaxel—kidney cancer	1.65e-05	7.87e-05	CcSEcCtD
Bortezomib—Dermatitis—Paclitaxel—kidney cancer	1.65e-05	7.87e-05	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—kidney cancer	1.64e-05	7.83e-05	CcSEcCtD
Bortezomib—Headache—Paclitaxel—kidney cancer	1.64e-05	7.82e-05	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—kidney cancer	1.63e-05	7.78e-05	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—kidney cancer	1.6e-05	7.63e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Capecitabine—kidney cancer	1.58e-05	7.55e-05	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—kidney cancer	1.57e-05	7.51e-05	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—kidney cancer	1.57e-05	7.48e-05	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—kidney cancer	1.56e-05	7.44e-05	CcSEcCtD
Bortezomib—Nausea—Paclitaxel—kidney cancer	1.55e-05	7.42e-05	CcSEcCtD
Bortezomib—Asthenia—Capecitabine—kidney cancer	1.54e-05	7.35e-05	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—kidney cancer	1.53e-05	7.3e-05	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—kidney cancer	1.52e-05	7.27e-05	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—kidney cancer	1.52e-05	7.26e-05	CcSEcCtD
Bortezomib—Pruritus—Capecitabine—kidney cancer	1.52e-05	7.25e-05	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—kidney cancer	1.52e-05	7.25e-05	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—kidney cancer	1.5e-05	7.15e-05	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—kidney cancer	1.49e-05	7.11e-05	CcSEcCtD
Bortezomib—Cough—Doxorubicin—kidney cancer	1.48e-05	7.06e-05	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—kidney cancer	1.47e-05	7.01e-05	CcSEcCtD
Bortezomib—Diarrhoea—Capecitabine—kidney cancer	1.47e-05	7.01e-05	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—kidney cancer	1.46e-05	6.99e-05	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—kidney cancer	1.44e-05	6.89e-05	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—kidney cancer	1.44e-05	6.89e-05	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—kidney cancer	1.44e-05	6.89e-05	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—kidney cancer	1.44e-05	6.87e-05	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.43e-05	6.84e-05	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—kidney cancer	1.43e-05	6.81e-05	CcSEcCtD
Bortezomib—Dizziness—Capecitabine—kidney cancer	1.42e-05	6.78e-05	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—kidney cancer	1.4e-05	6.66e-05	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—kidney cancer	1.38e-05	6.61e-05	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—kidney cancer	1.38e-05	6.61e-05	CcSEcCtD
Bortezomib—Infection—Doxorubicin—kidney cancer	1.38e-05	6.56e-05	CcSEcCtD
Bortezomib—Vomiting—Capecitabine—kidney cancer	1.37e-05	6.52e-05	CcSEcCtD
Bortezomib—Shock—Doxorubicin—kidney cancer	1.36e-05	6.5e-05	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—kidney cancer	1.36e-05	6.48e-05	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—kidney cancer	1.36e-05	6.47e-05	CcSEcCtD
Bortezomib—Rash—Capecitabine—kidney cancer	1.35e-05	6.46e-05	CcSEcCtD
Bortezomib—Dermatitis—Capecitabine—kidney cancer	1.35e-05	6.46e-05	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—kidney cancer	1.35e-05	6.45e-05	CcSEcCtD
Bortezomib—Headache—Capecitabine—kidney cancer	1.35e-05	6.42e-05	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—kidney cancer	1.34e-05	6.42e-05	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—kidney cancer	1.34e-05	6.39e-05	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—kidney cancer	1.32e-05	6.3e-05	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—kidney cancer	1.29e-05	6.17e-05	CcSEcCtD
Bortezomib—Nausea—Capecitabine—kidney cancer	1.28e-05	6.09e-05	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.26e-05	6.02e-05	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—kidney cancer	1.25e-05	5.98e-05	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—kidney cancer	1.24e-05	5.93e-05	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—kidney cancer	1.23e-05	5.89e-05	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—kidney cancer	1.22e-05	5.82e-05	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—kidney cancer	1.2e-05	5.74e-05	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.2e-05	5.7e-05	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—kidney cancer	1.19e-05	5.7e-05	CcSEcCtD
Bortezomib—Pain—Doxorubicin—kidney cancer	1.18e-05	5.65e-05	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—kidney cancer	1.18e-05	5.65e-05	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—kidney cancer	1.14e-05	5.44e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—kidney cancer	1.13e-05	5.4e-05	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—kidney cancer	1.1e-05	5.25e-05	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—kidney cancer	1.09e-05	5.22e-05	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—kidney cancer	1.09e-05	5.22e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—kidney cancer	1.02e-05	4.87e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—kidney cancer	9.93e-06	4.74e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—kidney cancer	9.79e-06	4.67e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—kidney cancer	9.47e-06	4.52e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—kidney cancer	9.15e-06	4.37e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—kidney cancer	8.8e-06	4.2e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—kidney cancer	8.73e-06	4.17e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—kidney cancer	8.72e-06	4.16e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—kidney cancer	8.67e-06	4.14e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—kidney cancer	8.22e-06	3.92e-05	CcSEcCtD
Bortezomib—PSMB1—Disease—MYC—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—RAF1—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—RAF1—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—RAF1—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PSMD7—kidney cancer	2.95e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—kidney cancer	2.94e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—RELA—kidney cancer	2.94e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—RELA—kidney cancer	2.94e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—RELA—kidney cancer	2.94e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTEN—kidney cancer	2.93e-06	1.96e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.93e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB2—kidney cancer	2.92e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB2—kidney cancer	2.92e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB2—kidney cancer	2.92e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—kidney cancer	2.91e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—kidney cancer	2.91e-06	1.95e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SLC2A1—kidney cancer	2.91e-06	1.94e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—RAF1—kidney cancer	2.91e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.9e-06	1.94e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—RELA—kidney cancer	2.89e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ITPR2—kidney cancer	2.89e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MAPK1—kidney cancer	2.89e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MAPK1—kidney cancer	2.89e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MAPK1—kidney cancer	2.89e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MTOR—kidney cancer	2.88e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MTOR—kidney cancer	2.88e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MTOR—kidney cancer	2.88e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB2—kidney cancer	2.88e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ACHE—kidney cancer	2.86e-06	1.91e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTT1—kidney cancer	2.86e-06	1.91e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ITPR2—kidney cancer	2.86e-06	1.91e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MAPK1—kidney cancer	2.85e-06	1.9e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MTOR—kidney cancer	2.84e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.82e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.81e-06	1.88e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PGK1—kidney cancer	2.81e-06	1.88e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK3—kidney cancer	2.81e-06	1.88e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—BCHE—kidney cancer	2.8e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MAPK3—kidney cancer	2.79e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK3—kidney cancer	2.78e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PIK3CA—kidney cancer	2.77e-06	1.85e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC5A5—kidney cancer	2.76e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PIK3CA—kidney cancer	2.76e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LDHB—kidney cancer	2.76e-06	1.84e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PIK3CA—kidney cancer	2.74e-06	1.83e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—kidney cancer	2.73e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—kidney cancer	2.73e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—kidney cancer	2.73e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—kidney cancer	2.73e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—kidney cancer	2.72e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PIK3CA—kidney cancer	2.71e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PIK3CA—kidney cancer	2.71e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PIK3CA—kidney cancer	2.71e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SCARB1—kidney cancer	2.71e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—kidney cancer	2.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1B—kidney cancer	2.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1B—kidney cancer	2.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1B—kidney cancer	2.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—kidney cancer	2.69e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS1—kidney cancer	2.68e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PIK3CA—kidney cancer	2.68e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK1—kidney cancer	2.67e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC2A1—kidney cancer	2.67e-06	1.78e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1B—kidney cancer	2.66e-06	1.78e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MAPK1—kidney cancer	2.66e-06	1.78e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—kidney cancer	2.64e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—kidney cancer	2.64e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—kidney cancer	2.64e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK1—kidney cancer	2.64e-06	1.77e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.64e-06	1.77e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTT1—kidney cancer	2.63e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ACHE—kidney cancer	2.63e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CRABP1—kidney cancer	2.63e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PSMD7—kidney cancer	2.63e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ACHE—kidney cancer	2.61e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTT1—kidney cancer	2.61e-06	1.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—kidney cancer	2.61e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.59e-06	1.73e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—kidney cancer	2.58e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—kidney cancer	2.58e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—kidney cancer	2.58e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—JUN—kidney cancer	2.57e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—JUN—kidney cancer	2.57e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—JUN—kidney cancer	2.57e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—kidney cancer	2.55e-06	1.71e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—kidney cancer	2.55e-06	1.71e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—kidney cancer	2.55e-06	1.71e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—kidney cancer	2.54e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—JUN—kidney cancer	2.54e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—kidney cancer	2.52e-06	1.69e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—kidney cancer	2.52e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—kidney cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—kidney cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—kidney cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—kidney cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—kidney cancer	2.5e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—BCHE—kidney cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SCARB1—kidney cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—kidney cancer	2.49e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—kidney cancer	2.49e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—kidney cancer	2.49e-06	1.66e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SCARB1—kidney cancer	2.47e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—kidney cancer	2.47e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS1—kidney cancer	2.47e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC5A5—kidney cancer	2.46e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.46e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.46e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—kidney cancer	2.45e-06	1.64e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ITPR2—kidney cancer	2.45e-06	1.64e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS1—kidney cancer	2.45e-06	1.64e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—kidney cancer	2.43e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSMD7—kidney cancer	2.42e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSMD7—kidney cancer	2.4e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CA9—kidney cancer	2.39e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC2A1—kidney cancer	2.38e-06	1.59e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—kidney cancer	2.32e-06	1.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.31e-06	1.54e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—kidney cancer	2.3e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCB1—kidney cancer	2.3e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—BCHE—kidney cancer	2.29e-06	1.53e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—kidney cancer	2.29e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—BCHE—kidney cancer	2.27e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC5A5—kidney cancer	2.27e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.26e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.26e-06	1.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—kidney cancer	2.25e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—kidney cancer	2.25e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—kidney cancer	2.25e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC5A5—kidney cancer	2.25e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—kidney cancer	2.24e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—POMC—kidney cancer	2.24e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ACHE—kidney cancer	2.23e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—kidney cancer	2.23e-06	1.49e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—kidney cancer	2.23e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—kidney cancer	2.23e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—kidney cancer	2.22e-06	1.49e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—kidney cancer	2.22e-06	1.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—kidney cancer	2.22e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC2A1—kidney cancer	2.19e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC2A1—kidney cancer	2.17e-06	1.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—kidney cancer	2.13e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—kidney cancer	2.13e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—kidney cancer	2.13e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SCARB1—kidney cancer	2.11e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.11e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—kidney cancer	2.11e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—kidney cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—kidney cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—kidney cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—kidney cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS1—kidney cancer	2.09e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—kidney cancer	2.07e-06	1.38e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—kidney cancer	2.07e-06	1.38e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—kidney cancer	2.07e-06	1.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—kidney cancer	2.07e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMD7—kidney cancer	2.05e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—kidney cancer	2.04e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—kidney cancer	2.04e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CRABP1—kidney cancer	2.03e-06	1.36e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK1—kidney cancer	2.02e-06	1.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK1—kidney cancer	2.02e-06	1.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK1—kidney cancer	2.02e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.01e-06	1.35e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK1—kidney cancer	1.99e-06	1.33e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—kidney cancer	1.99e-06	1.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BCHE—kidney cancer	1.94e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A1—kidney cancer	1.94e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.92e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—kidney cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—kidney cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—kidney cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ITPR2—kidney cancer	1.89e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—kidney cancer	1.88e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—kidney cancer	1.88e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.85e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.84e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—kidney cancer	1.83e-06	1.22e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—kidney cancer	1.82e-06	1.22e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—kidney cancer	1.81e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.8e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—kidney cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—kidney cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—kidney cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—kidney cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.74e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—kidney cancer	1.73e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A1—kidney cancer	1.73e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—kidney cancer	1.73e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.72e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ACHE—kidney cancer	1.72e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—kidney cancer	1.71e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—kidney cancer	1.7e-06	1.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—kidney cancer	1.7e-06	1.14e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—kidney cancer	1.7e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—kidney cancer	1.68e-06	1.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—kidney cancer	1.67e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—kidney cancer	1.66e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SCARB1—kidney cancer	1.63e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS1—kidney cancer	1.61e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.59e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.59e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMD7—kidney cancer	1.58e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A1—kidney cancer	1.58e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—kidney cancer	1.58e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.57e-06	1.05e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—kidney cancer	1.56e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—kidney cancer	1.55e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BCHE—kidney cancer	1.5e-06	1e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.48e-06	9.91e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—kidney cancer	1.46e-06	9.79e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—kidney cancer	1.44e-06	9.66e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.43e-06	9.57e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—kidney cancer	1.42e-06	9.5e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.42e-06	9.5e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1A1—kidney cancer	1.35e-06	9.01e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.3e-06	8.66e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—kidney cancer	1.29e-06	8.62e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—kidney cancer	1.26e-06	8.4e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—kidney cancer	1.19e-06	7.98e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—kidney cancer	1.19e-06	7.93e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—kidney cancer	1.18e-06	7.86e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—kidney cancer	1.15e-06	7.7e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—kidney cancer	1.13e-06	7.56e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.11e-06	7.4e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—kidney cancer	1.1e-06	7.34e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.1e-06	7.34e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—kidney cancer	1.1e-06	7.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.04e-06	6.95e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—kidney cancer	1.03e-06	6.88e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—kidney cancer	1e-06	6.72e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—kidney cancer	1e-06	6.72e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—kidney cancer	9.46e-07	6.32e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—kidney cancer	9.38e-07	6.27e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—kidney cancer	8.97e-07	6e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—kidney cancer	8.25e-07	5.52e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—kidney cancer	8.18e-07	5.47e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—kidney cancer	8.01e-07	5.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—kidney cancer	7.75e-07	5.18e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—kidney cancer	7.73e-07	5.17e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—kidney cancer	7.09e-07	4.74e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—kidney cancer	6.99e-07	4.67e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—kidney cancer	6.33e-07	4.23e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—kidney cancer	6.18e-07	4.14e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—kidney cancer	5.82e-07	3.89e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—kidney cancer	5.77e-07	3.86e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—kidney cancer	5.39e-07	3.61e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—kidney cancer	4.93e-07	3.3e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.8e-07	2.54e-06	CbGpPWpGaD
